Manza Peter, Tomasi Dardo, Demiral Şükrü Barış, Shokri-Kojori Ehsan, Lildharrie Christina, Lin Esther, Wang Gene-Jack, Volkow Nora D
Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD 20892.
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland School of Medicine, Baltimore, MD 21201.
Proc Natl Acad Sci U S A. 2025 Apr;122(13):e2423785122. doi: 10.1073/pnas.2423785122. Epub 2025 Mar 24.
Stimulant drugs that boost dopamine, like methylphenidate (MP), enhance attention and are effective treatments for attention-deficit hyperactivity disorder (ADHD). Yet there is large individual variation in attentional capacity and response to MP. It is unclear whether this variation is driven by individual differences in relative density of dopamine receptor subtypes, magnitude of dopamine increases induced by MP, or both. Here, we extensively characterized the brain dopamine system with positron emission tomography (PET) imaging (including striatal dopamine D1 and D2/3 receptor availability and MP-induced dopamine increases) and measured attention task-evoked fMRI brain activity in two separate sessions (placebo and 60 mg oral MP; single-blind, counterbalanced) in 37 healthy adults. A network of lateral frontoparietal and visual cortices was sensitive to increasing attentional (and working memory) load, whose activity positively correlated with performance across individuals (partial r = 0.474, = 0.008; controlling for age). MP-induced change in activity within this network correlated with MP-induced change in performance (partial r = 0.686, < 0.001). The ratio of D1-to-D2/3 receptors in dorsomedial caudate positively correlated with baseline attentional network activity and negatively correlated with MP-induced changes in activity (all pFWE < 0.02). MP-induced changes in attentional load network activity mediated the association between D1-to-D2/3 ratio and MP-induced improvements in performance (mediation estimate = 23.20 [95%CI: -153.67 -81.79], = 0.004). MP attention-boosting effects were not linked to the magnitude of striatal dopamine increases, but rather showed dependence on an individual's baseline receptor density. Individuals with lower D1-to-D2/3 ratios tended to have lower frontoparietal activity during sustained attention and experienced greater improvement in brain function and task performance with MP.
像哌甲酯(MP)这类能提升多巴胺水平的兴奋剂药物,可增强注意力,是治疗注意力缺陷多动障碍(ADHD)的有效方法。然而,注意力容量和对MP的反应存在很大的个体差异。目前尚不清楚这种差异是由多巴胺受体亚型的相对密度个体差异、MP诱导的多巴胺增加幅度,还是两者共同驱动的。在此,我们用正电子发射断层扫描(PET)成像广泛表征了大脑多巴胺系统(包括纹状体多巴胺D1和D2/3受体可用性以及MP诱导的多巴胺增加),并在37名健康成年人的两个独立时间段(安慰剂和60毫克口服MP;单盲、平衡设计)测量了注意力任务诱发的功能磁共振成像(fMRI)大脑活动。外侧额顶叶和视觉皮层网络对注意力(和工作记忆)负荷增加敏感,其活动与个体表现呈正相关(偏相关系数r = 0.474,P = 0.008;控制年龄因素)。MP诱导的该网络内活动变化与MP诱导的表现变化相关(偏相关系数r = 0.686,P < 0.001)。背内侧尾状核中D1与D2/3受体的比例与基线注意力网络活动呈正相关,与MP诱导的活动变化呈负相关(所有校正后P < 0.02)。MP诱导的注意力负荷网络活动变化介导了D1与D2/3比例和MP诱导的表现改善之间的关联(中介效应估计值 = 23.20 [95%置信区间:-153.67 -81.79],P = 0.004)。MP的注意力增强效应与纹状体多巴胺增加幅度无关,而是依赖于个体的基线受体密度。D1与D2/3比例较低的个体在持续注意力期间额顶叶活动往往较低,并且使用MP后大脑功能和任务表现有更大改善。